Kimberly-Clark bets $40 billion for Kenvue despite Tylenol controversy
                    
                        By Juveria Tabassum and Sriparna Roy (Reuters) -Kimberly-Clark is laying down $40 billion to buy Kenvue in a massive deal that has puzzled some investors as the Tylenol maker struggles with weak sales, lawsuits and White House attacks linking its painkiller...                    
                    
                        
                        
                            Reuters